Every 8-K that SunLink Health Systems, Inc (SSY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SSY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SSY filings page.
SunLink Health Systems, Inc. completed its previously announced merger with Regional Health Properties, Inc. effective August 14, 2025, with SunLink merging into Regional and Regional continuing as the surviving corporation. At the effective time, each five shares of SunLink common stock were converted into the right to receive 1.1330 shares of Regional common stock and one share of Regional Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares, with cash paid in lieu of fractional shares. The total consideration was approximately 1,595,400 Regional common shares and approximately 1,408,120 Regional Series D preferred shares.
SunLink common shareholders ceased to have any rights as SunLink shareholders other than to receive this merger consideration. SunLink notified NYSE American that the merger would be effective at 5:00 p.m. Eastern Time on August 14, 2025, and NYSE American is expected to file Form 25 to remove SunLink common stock from listing and registration, followed by a Form 15 to deregister the shares and suspend reporting obligations. At the effective time, a change in control occurred, SunLink’s directors and key officers resigned, and former President and CEO Robert M. Thornton, Jr. waived all rights to compensation, severance, and change in control benefits under his employment agreement.
SunLink Health Systems (NYSE American: SSY) filed an amended Form 8-K to update investors on two items tied to its pending merger with Regional Health Properties.
- $0.10 special cash dividend: Board declared the dividend for holders of record 29 Jul 2025, payable 30 Jul 2025. Trades from 29-30 Jul will carry due-bills. Aggregate dividends allowed under the merger pact are capped at $1.0 million.
- Merger status: The Amended & Restated Merger Agreement (original 14 Apr 2025) was further amended 22 Jun 2025 to extend the termination date to 11 Aug 2025 and make minor clarifications. SunLink will merge into Regional, which will be the surviving entity.
The Board may revoke or postpone the dividend if (a) SunLink shareholders fail to approve the merger at the 29 Jul 2025 special meeting, (b) the agreement is terminated, amended or further extended, or (c) other conditions arise. Closing remains subject to customary conditions including both shareholder votes, effectiveness of Regional’s Form S-4 (declared effective 25 Jun 2025), and listing approvals for Regional stock.
No financial results were reported; this filing is strictly an update on corporate actions related to the merger and dividend.
SunLink Health Systems, Inc. (SSY) filed a Form 8-K to disclose an Amendment to the Amended & Restated Agreement and Plan of Merger with Regional Health Properties, Inc. The amendment, signed 22 June 2025, extends the Merger Agreement’s “Termination Date” from 30 June 2025 to 11 August 2025 (5:00 p.m. ET) and makes a minor clean-up revision.
The extension was needed because neither SunLink nor Regional has yet received their respective shareholder approvals. Both boards determined that the approvals could not be obtained by the original deadline and therefore agreed to push back the outside date. All other material terms of the Merger Agreement remain unchanged. Either party may still terminate the deal if the merger is not consummated by the new deadline.
No financial statements, earnings metrics, or revised merger economics were included in this filing. Exhibit 2.1 contains the full text of the amendment, and an Inline XBRL cover page (Exhibit 104) was provided.
- The filing reiterates that the joint proxy statement/prospectus will be filed on Form S-4 and urges investors to read it once available.
- The company restates customary “no offer or solicitation” language and an extensive list of forward-looking risk factors.
Investor takeaway: The merger remains pending but now faces at least a six-week delay, highlighting continued execution risk tied to securing shareholder and regulatory approvals.